Last Price
0.005
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Overview
Market Cap
11 Million
Shares Outstanding
2 Billion
Avg Volume
2,491,746
Avg Price (50 Days)
0.01
Avg Price (200 Days)
0.01
PE Ratio
-0.25
EPS
-0.02
Earnings Announcement
28-Aug-2025
Previous Close
0.01
Open
0.01
Day's Range
0.005 - 0.005
Year Range
0.004 - 0.039
Trading Volume
4,190,147
Price Change Highlight
1 Day Change
5 Day Change
1 Month Change
3 Month Change
6 Month Change
Ytd Change
1 Year Change
3 Year Change
5 Year Change
10 Year Change
Max Change
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
.png)
.png)
Apps
Top Articles
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
